01PEPTIDE
Retatrutide
GLP-1 / GIP / Glucagon triple agonist for substantial weight loss and metabolic improvement.
Weight ManagementAppetiteGlucose / Insulin
EXPLORE THIS GOAL · PB
Body Composition research
Body Composition records within Performance + Body Composition. Structured links are generated from shared research-goal tags.
01
Relevant peptides
02PEPTIDE
Tirzepatide
Dual GIP / GLP-1 receptor agonist for superior weight loss and glycemic control.
Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE
Semaglutide
Long-acting selective GLP-1 receptor agonist for weight loss and glycemic control.
Weight ManagementAppetiteGlucose / Insulin
04PEPTIDE
Cagrilintide
Long-acting amylin analog for appetite regulation and weight management (often studied with semaglutide as CagriSema).
Weight ManagementAppetiteFat Loss
05PEPTIDE
Cagrilintide + Semaglutide (CagriSema)
Fixed dual combination of long-acting amylin analog + GLP-1 agonist for enhanced weight loss.
Weight ManagementAppetiteGlucose / Insulin
06PEPTIDE
Tesamorelin
Synthetic GHRH analog that stimulates endogenous GH release for visceral fat reduction.
Body CompositionFat LossNeuroendocrine
07PEPTIDE
AOD 9604
Modified hGH fragment (176-191) studied for lipolysis without significant IGF-1 elevation.
Fat LossWeight ManagementBody Composition
08PEPTIDE
5-Amino-1MQ
A small-molecule NNMT inhibitor studied primarily in preclinical metabolic and adipose-tissue models.
Fat LossBody CompositionMetabolic
09PEPTIDE
Survodutide
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
Weight ManagementAppetiteFat Loss
10PEPTIDE
Mazdutide
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
Weight ManagementGlucose / InsulinFat Loss
11PEPTIDE
Pemvidutide
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Weight ManagementFat LossBody Composition
12PEPTIDE
Ipamorelin
Selective growth hormone secretagogue (GHRP) with minimal effect on cortisol or prolactin.
NeuroendocrineBody CompositionRecovery
13PEPTIDE
CJC-1295 (with DAC)
Long-acting GHRH analog that provides sustained GH and IGF-1 elevation for several days.
NeuroendocrineBody CompositionRecovery
14PEPTIDE
Sermorelin
Short-acting GHRH analog that amplifies the body’s natural growth-hormone pulses.
NeuroendocrineBody CompositionRecovery
02
Related protocols
03
Popular comparisons
04
Related research
SPONSOR UPDATETRIUMPH-1 Phase 3 topline resultsRetatrutide · Eli Lilly and Company · 2026SPONSOR UPDATETRIUMPH-2 and TRIUMPH-3 Phase 3 topline results and planned regulatory submissionRetatrutide · Eli Lilly and Company · 2026REGULATORYWhat to know about retatrutideRetatrutide · Eli Lilly and Company · 2026CLINICAL TRIALCoadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityCagrilintide + Semaglutide (CagriSema) · New England Journal of Medicine · 2025CLINICAL TRIALTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver diseaseRetatrutide · Nature Medicine · 2024CLINICAL TRIALGlucagon and GLP-1 receptor dual agonist survodutide for obesitySurvodutide · The Lancet Diabetes & Endocrinology · 2024
05
Tools
06
Related goals
BUILD FROM THIS RESEARCH CONTEXT
Build a stack for Body Composition
The goal stays visible in the stack builder. Related records are suggestions by tag overlap; you choose what to add.